Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BD launches New Safety Blood Collection Needle with Flashback Chamber

Published: Wednesday, October 03, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
Intuitive, easy-to-use, single-handed activation device combines safety with added reassurance of flashback for the confidence of success.

BD (Becton, Dickinson and Company) has announces the launch of the new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle in Europe. The safety-engineered design with single-handed activation, integrated holder and a new flashback chamber offers healthcare workers immediate confirmation of venous access, whilst also reducing the potential for sharps injuries.

Blood collection is one of the most hazardous tasks healthcare workers perform. A European study[i] revealed that it is the procedure with the highest risk of needlestick injury compared to other clinical procedures. A single needlestick injury can expose a healthcare worker to one or more of 30 potentially dangerous blood-borne pathogens, including Hepatitis B, Hepatitis C and HIV.

Luis Fernandez-Inglesias, Vice President, BD Diagnostics, Preanalytical Systems Europe, says: “BD is committed to raising awareness of the risks faced by healthcare workers and educating and informing healthcare facilities on the precautions they can adopt, as well as developing safety-engineered devices for improving healthcare worker safety. The new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle represents a new level of confidence in safety-engineered devices for venous blood collection, designed specifically with healthcare workers’ safety in mind and ease of use.”

The BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle allows immediate confirmation of venous access, which is indicated by the presence of blood in the flashback chamber, providing confidence during venepuncture. Other key ergonomic features which make venous blood collection simple and more comfortable, are the new anti-slip ridges and thumb pad for easy, single-handed activation of the safety shield. The blood droplet reduction system is designed to reduce blood droplet formation when the needle is removed from the vein, and the needle bevel and safety shield are aligned for easy identification of the needle position for blood collection. Full integration of the holder and needle reduces the risk of user-end sharps injuries and improves efficiency by reducing the number of steps in the blood collection process, with no compromise to patient care.

Mr Kor Kooi, PreAnalytical Manager at UMCG Hospital Groningen, one of the biggest University Hospitals in the Netherlands and the first site in Europe to order the BD Vacutainer® Eclipse™ Signal™, explains: "At Groningen, this new blood collection needle will provide an extra tool to use when carrying out these very important procedures.  The flashback chamber makes it much easier to determine if blood collection has been successful, and this invaluable feature also reduces the potential for patient discomfort."

It is estimated that one million sharps injuries occur in the European Union each year[iii], with more than 100,000 each year in the UK alone[iv]. The EU Directive on the prevention of sharps injuries in the hospital and healthcare sector[v] must be transposed into national law of all EU member states by 11 May 2013, placing an obligation on healthcare organisations “to achieve the safest possible working environment by preventing injuries to workers caused by all medical sharps”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Launches New Europe-wide Healthcare Worker Safety Website
Designed to help healthcare workers stay safe and minimise their risk of sharps injury.
Tuesday, June 12, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!